The University of Southampton
University of Southampton Institutional Repository

Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: a systematic review and meta-analysis

Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: a systematic review and meta-analysis
Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: a systematic review and meta-analysis
Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.

Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.

Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD −1.54 days, 95% CI [−2.15,−0.92], I2 = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI [−1.52, −0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [−1.15, −0.21], I2 = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI [−1.23, −0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI [−1.36, −0.90], I2 = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI [−1.40, −0.86], I2 = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1–5 days). No serious adverse events were reported.

Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.
Chinese herbal medicine, Randomized controlled trials, Respiratory tract infections, Shufeng Jiedu, Systematic review
2213-4220
Liu, Jian Ping
4c1de9c3-e9c2-4d4e-a0a4-dad123a39c76
Zhang, Ying
a1a5b530-992a-41b3-94d8-043590122036
Xia, Ru-yu
93e6664d-40f0-43e8-b156-e0d037404694
Liang, Shi-bing
2a2dd82a-23b1-437c-9c02-625dfea79fd4
Hu, Xiao-yang
baaa5988-cab4-4233-beca-2776b02de0c0
Dai, Meng-yuan
9b892c25-42d8-4937-972f-ed2fd69b65ac
Li, Yi-lin
31a77ba4-da04-4e5d-9e36-52dbf76b0c60
Zhao, Le-yi
5ae4dca4-e4fd-4bcb-ad67-22f07457547f
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Fei, Yu-tong
8a9bd568-ead2-4fcf-81e5-861ba50d6d6a
Liu, Jian-ping
1ac69bb8-ead3-44be-91d1-d3ed8554a9e9
Hu, Xiaoyang
65904b24-3775-4b14-9532-eb703a056655
Liu, Jian Ping
4c1de9c3-e9c2-4d4e-a0a4-dad123a39c76
Zhang, Ying
a1a5b530-992a-41b3-94d8-043590122036
Xia, Ru-yu
93e6664d-40f0-43e8-b156-e0d037404694
Liang, Shi-bing
2a2dd82a-23b1-437c-9c02-625dfea79fd4
Hu, Xiao-yang
baaa5988-cab4-4233-beca-2776b02de0c0
Dai, Meng-yuan
9b892c25-42d8-4937-972f-ed2fd69b65ac
Li, Yi-lin
31a77ba4-da04-4e5d-9e36-52dbf76b0c60
Zhao, Le-yi
5ae4dca4-e4fd-4bcb-ad67-22f07457547f
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Fei, Yu-tong
8a9bd568-ead2-4fcf-81e5-861ba50d6d6a
Liu, Jian-ping
1ac69bb8-ead3-44be-91d1-d3ed8554a9e9
Hu, Xiaoyang
65904b24-3775-4b14-9532-eb703a056655

Liu, Jian Ping, Zhang, Ying, Xia, Ru-yu, Liang, Shi-bing, Hu, Xiao-yang, Dai, Meng-yuan, Li, Yi-lin, Zhao, Le-yi, Moore, Michael, Fei, Yu-tong, Liu, Jian-ping and Hu, Xiaoyang (2021) Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: a systematic review and meta-analysis. Integrative Medicine Research, 10 (3), [100726]. (doi:10.1016/j.imr.2021.100726).

Record type: Article

Abstract

Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.

Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.

Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD −1.54 days, 95% CI [−2.15,−0.92], I2 = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI [−1.52, −0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [−1.15, −0.21], I2 = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI [−1.23, −0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI [−1.36, −0.90], I2 = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI [−1.40, −0.86], I2 = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1–5 days). No serious adverse events were reported.

Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.

Text
1-s2.0-S2213422021000135-main - Version of Record
Download (1MB)

More information

Accepted/In Press date: 22 March 2021
e-pub ahead of print date: 2 April 2021
Published date: September 2021
Additional Information: Funding Information: This work is supported by the National Key Research and Development Project: Adding Chinese herbal medicine to antibiotic treatment for acute exacerbation of chronic obstructive pulmonary disease (Grant no. 2018YFE0102300). Publisher Copyright: © 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
Keywords: Chinese herbal medicine, Randomized controlled trials, Respiratory tract infections, Shufeng Jiedu, Systematic review

Identifiers

Local EPrints ID: 449381
URI: http://eprints.soton.ac.uk/id/eprint/449381
ISSN: 2213-4220
PURE UUID: 3fe77ee8-50cd-4cba-be56-9935adafbbf9
ORCID for Michael Moore: ORCID iD orcid.org/0000-0002-5127-4509
ORCID for Xiaoyang Hu: ORCID iD orcid.org/0000-0002-3143-7999

Catalogue record

Date deposited: 26 May 2021 16:32
Last modified: 28 Apr 2022 02:14

Export record

Altmetrics

Contributors

Author: Jian Ping Liu
Author: Ying Zhang
Author: Ru-yu Xia
Author: Shi-bing Liang
Author: Xiao-yang Hu
Author: Meng-yuan Dai
Author: Yi-lin Li
Author: Le-yi Zhao
Author: Michael Moore ORCID iD
Author: Yu-tong Fei
Author: Jian-ping Liu
Author: Xiaoyang Hu ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×